Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery

NCT ID: NCT00393848

Last Updated: 2014-06-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-10-31
• Study Completion Date: 2012-10-31

Brief Summary

The purpose of this study is to determine the effects of two postoperative interventions designed to preserve muscle protein after major hip or knee surgery.

Detailed Description

Hip fractures among the elderly are a major health concern. Nearly one-third of elderly hip fracture patients die within 1 year of the injury. Events surrounding the actual injury and any necessary surgical repair often lead to reduced muscle protein, and eventually, muscle strength. Loss in everyday function and independence may follow, especially in elderly or frail individuals. The decrease in protein synthesis may be caused by two main events following injury and surgery: prolonged inactivity and an increase in stress hormone levels. Preventing a loss in protein may help to improve outcomes for individuals undergoing hip surgery and rehabilitation. The purpose of this study is to determine the effects of two postoperative interventions designed to retain muscle protein after major hip or knee surgery in adults.

This study will include two experiments. Experiment 1 will include individuals who are scheduled for hip or knee replacement surgery because of osteoarthritis (the need to repair or replace the affected joint), or avascular necrosis (bone tissue death caused by lack of blood supply). Experiment 1 participants will be randomly assigned to one of two groups:

• Group 1 participants will receive daily supplements of essential amino acids, which are thought to stimulate protein synthesis.
• Group 2 participants will receive standard rehabilitation care while in the hospital and will serve as controls for the effect of time on recovery.

Participants will be in the hospital for about 4 days. On the morning of surgery, blood and urine collection will occur. During surgery, substances called tracers, measuring the extent of protein synthesis and breakdown, will be injected into a vein for the first metabolic study. Additional blood and muscle samples will also be taken. After surgery, when participants arrive in the surgical recovery unit and are able to eat, they will begin to record all food intake and will receive their assigned treatment. Treatment, in the form of gel capsules, will be taken 2.5 hours after each meal. Urine will be collected throughout hospitalization and blood will be collected each morning. Prior to discharge, a 24-hour metabolic study will be performed, including tracer injections and muscle biopsies. After discharge, participants will be provided with 6 weeks' worth of their assigned treatment. Follow-up visits will occur 2 and ~6 to 8 weeks after surgery. These visits will include various muscle function and physical performance tests. Participants will also undergo a dual energy x-ray absorptiometry (DEXA) scan, which will be used to determine muscle mass.

Experiment 2 participants will include individuals scheduled for either hip or knee replacement surgery or fracture repair surgery. Participants will be randomly assigned to one of two groups:

• Group 1 participants will receive the antifungal drug ketoconazole, which is thought to reduce levels of the stress hormone cortisol.
• Group 2 participants will receive placebo and standard rehabilitation care while in the hospital.

Participants will begin taking their assigned treatments the day prior to surgery; those with a hip fracture will take their assigned treatment at least 4 hours prior to surgery. The same procedures that occurred in Experiment 1 during surgery and hospitalization will be carried out during Experiment 2. The second metabolic study, however, will last only 1 hour and will include a standard clinical meal.

Conditions

Hip Fracture; Osteoarthritis; Femur Head Necrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Experiment 2 - Experimental Group

Group Type: EXPERIMENTAL

Ketoconazole

Intervention Type: DRUG

200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.

Experiment 1 - Standard of care Group

Group Type: NO_INTERVENTION

No interventions assigned to this group

Experiment 1 - Experimental Group

Group Type: EXPERIMENTAL

Essential amino acid supplement

Intervention Type: DRUG

15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.

Experiment 2 - Placebo Group

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo for Ketoconazole

Interventions

Essential amino acid supplement

15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.

Intervention Type: DRUG

Ketoconazole

200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.

Intervention Type: DRUG

Placebo

Placebo for Ketoconazole

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Scheduled for surgery because of osteoarthritis, avascular necrosis, fracture, or revision of total joint replacement in the hip or knee

Exclusion Criteria

• Taking insulin, thiazolidinediones (TZD), or metformin
• Kidney insufficiency, as indicated by serum creatinine of more than 2.0 mg/dl
• Recently treated cancer other than basal cell carcinoma
• Any other condition or event that would be considered as reason for exclusion by the study investigators
• Pregnancy

• Severe hypertension as indicated by requiring more than two drugs for blood pressure control
• History of hypo- or hypercoagulation disorders, including individuals who have taken warfarin (Coumadin)
• Atrial fibrillation, angina, or congestive heart failure

• Liver disease or abnormal liver function tests
• HIV infected
• Active hepatitis
• Any uncontrolled metabolic disease, including liver or kidney disease
• Taking medications that use the cytochrome P450 pathway for metabolism and unable to discontinue their use for the duration of the study
• Require certain medications. More information on this criterion can be found in the protocol.
• Gastrointestinal absorption disorders that affect nutrient uptake

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

Sponsor Role: collaborator

University of Arkansas

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Arny Ferrando, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Arkansas

Locations

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Countries

United States

Other Identifiers

70451

Identifier Type: -

Identifier Source: secondary_id

1R01AR052293-01A2

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R01AR052293

Identifier Type: NIH

Identifier Source: org_study_id

View Link